AmeriHealth Mercy/PerformRx to Present at Specialty
Pharmaceutical Management Strategies Conference
March 12, 2004 - Philadelphia (PA) - Mesfin Tegenu,
MS, RPh, Vice President, Pharmacy Services, AmeriHealth Mercy,
will present on PerformRx,
AmeriHealth Mercy's pharmacy benefit management product, at
the first annual Specialty Pharmaceutical Management Strategies
for Health Plans and Employers in Chicago on Tuesday, March
16, 2004 at the Millennium Knickerbocker Hotel.
PerformRx
is the next generation pharmacy benefit management program
with a proven pharmacy care management solution that meets financial
objectives while improving the quality of health care for its
customers. Within the Medicaid sector, by using the approach
of linking traditional medical management with pharmacy management,
PerformRx maintains an average annual pharmacy cost trend of
less than 9% versus the national trend of 18%-25%.
Tegenu will be speaking about the AmeriHealth Mercy's three-year
old injectable program that has expanded to include all high
cost injectable and biological products. He will demonstrate
the program's success, including on patient outcomes and the
reduced financial impact on the health plan. He will also be
participating in the featured panel presentation, "Best
Practice Strategies to Avoid Duplicate Claims Payments that
Flow through Medical Pharmacy".
With more than 20 years of experience exclusively serving the
Medicaid population, AmeriHealth Mercy and its affiliates comprise
the largest family of Medicaid managed care plans in the United
States, touching the lives of more than one million members
in six states, Pennsylvania, New Jersey, Kentucky, South Carolina,
Virginia and California.
The two-day conference will address the major challenges payors
and large self-insured employers are currently facing with managing
high-cost, low-volume specialty pharmaceutical market. It will
also feature organizations presenting best practices, highlighting
ways in which they have managed the rising cost sand surrounding
challenges of specialty pharmaceuticals.
|